A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

The Sequence Alignment/Map format and SAMtools

Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data

Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,724

Fast and accurate long-read alignment with Burrows-Wheeler transform.

Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

PAK2 is essential for chromosome alignment in metaphase I oocytes

Zeng, J., Wang, S., Gao, M., Lu, D., Song, S., Chen, D., Fan, W., Xu, Z., Zhang, Z., & Sun, X. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05585-7 · Cited by 11

The Role of Yes‐Associated Protein in Inflammatory Diseases and Cancer

Zhong, B., Du, J., Liu, F., & Sun, S. (2025) · MedComm · doi:10.1002/mco2.70128 · Cited by 10

Suspension state and shear stress enhance breast tumor cells EMT through YAP by microRNA-29b

Zhao, B., & Lv, Y. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09661-6 · Cited by 11

Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer

Yonesaka, K., Kurosaki, T., Tanizaki, J., Kawakami, H., Tanaka, K., Maenishi, O., Takamura, S., Sakai, K., Chiba, Y., Teramura, T., et al. (2025) · Cells · doi:10.3390/cells14060447 · Cited by 9

An updated patent review of TEAD modulators (2022–present)

Xu, D., Zhong, J., Zeng, Y., Zhang, X., Wang, C., Luo, C., & Xiong, H. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2522747 · Cited by 9

FOXM1 Promotes Malignant Proliferation of Esophageal Squamous Cell Carcinoma Through Transcriptional Activating CDC6

Chen, X., Chen, J., Yu, X., Lin, G.-S., & Chen, T. (2022) · DNA and Cell Biology · doi:10.1089/dna.2022.0169 · Cited by 9

PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up

Lailler, C., Didelot, A., Garinet, S., Berthou, H., Sroussi, M., de Reyniès, A., Dedhar, S., Martin‐Lannerée, S., Fabre, E., Pimpec‐Barthes, F. L., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03130-0 · Cited by 9

The critical role of the Hippo signaling pathway in renal fibrosis

Zhao, C., Wang, H., Xu, C., Fang, F., Gao, L., Zhai, N., Zhong, Y., & Wang, X. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111661 · Cited by 8

CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer

Thiruvalluvan, M., Billet, S., Liu, Z., Lownik, J. C., Waissengrin, B., Kim, H., Villamejor, A. L., Milshteyn, L., Li, X., Gayhart, M. G., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101237 · Cited by 9

Computed Tomography-Based Radiomics to Predict FOXM1 Expression and Overall Survival in Patients with Clear Cell Renal Cell Carcinoma

Zhao, J., Zhang, Q., Chen, Y., & Zhao, X. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.01.036 · Cited by 8

Cancer on motors: How kinesins drive prostate cancer progression?

Wang, J., Zhang, F.-H., Liu, Z. L., Tang, Y.-J., Li, J., & Xie, L. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116229 · Cited by 9

Identification of a Twelve Epithelial-Mesenchymal Transition-Related lncRNA Prognostic Signature in Kidney Clear Cell Carcinoma

Xia, Q., Zhang, Y., Li, L., Lu, J., Xun, Y., Sun, J., Xu, J., Liu, C., Lu, Y., He, D., et al. (2022) · Disease Markers · doi:10.1155/2022/8131007 · Cited by 8

A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation

Li, L., Li, Y., Ma, X., Li, P., Zeng, S., Jiang, F., & Zhang, G. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108864 · Cited by 7

The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor–Resistant NSCLC and Drug-Tolerant Persister Cells

Yang, Y., Nilsson, M. B., Yu, X., Poteete, A., Jiang, H., Huang, Q., He, J., Heeke, S., & Heymach, J. V. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1693 · Cited by 7

Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy

Zhu, J., Wu, T., & Lin, Q. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08329-0 · Cited by 8

Sestrin2 mediates FOXM1 expression to block the EMT process in non-small cell lung cancer through the AMPK/YAP pathway

Wang, Y.-L., Wang, Q., Li, H., Wang, C.-C., Ma, Y., & Han, Z. (2023) · Neoplasma · doi:10.4149/neo_2022_220711n705 · Cited by 7

Polo-like kinase 1 promotes sepsis-induced myocardial dysfunction

Gao, Z., Zheng, C., Xing, Y., Zhang, X., Bai, Y., Chen, C., Zheng, Y., Wang, W., Zhang, H., & Meng, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111074 · Cited by 7

Dickkopf-1 promotes tumor progression of gefitinib- resistant non-small cell lung cancer through cancer cell-fibroblast interactions

Choi, M., Choi, Y. J., Lee, Y. J., Lee, Y., Chung, J. H., & Kang, K. W. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00616-9 · Cited by 8

The ETS transcription factor GABPA inhibits bladder cancer aggressiveness by repressing extracellular matrix deposition and mechanotransduction signaling

Dai, M., Yuan, X., Sun, C., Han, R., Björkholm, M., Kong, F., Zhao, S., & Xu, D. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07935-z · Cited by 7

Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy

Chen, Y., Dou, R., Hong, M. J., Xu, H., Vykoukal, J., Léon-Letelier, R. A., Cai, Y., Park, S., Irajizad, E., Hsiao, F. C., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102513 · Cited by 6

Mechanism of intrinsic resistance of lung squamous cell carcinoma to epithelial growth factor receptor‑tyrosine kinase inhibitors revealed by high‑throughput RNA interference screening

Ju, L., Dong, Z., Yang, J., & Li, M. (2020) · Oncology Letters · doi:10.3892/ol.2020.12218 · Cited by 6

Induction of Multiple Alternative Mitogenic Signaling Pathways Accompanies the Emergence of Drug-Tolerant Cancer Cells

Celeste, F., & Powers, S. (2024) · Cancers · doi:10.3390/cancers16051001 · Cited by 6

Discovery of repurposed ethacrynic acid and its derivatives as novel TEAD inhibitors

Chen, W., Nan, Y., Zhang, Y., Han, W., Wang, Y., Liu, B., & Li, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118299 · Cited by 5

Drug-tolerant persister cells in cancer: a scoping review of definitions, models, and molecular mechanisms

López-González, J. S., Perez-Medina, M., Galicia-Velasco, M., & Aguilar‐Cázares, D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771061 · Cited by 5

FOXM1 Transcriptionally Co-Upregulates Centrosome Amplification and Clustering Genes and Is a Biomarker for Poor Prognosis in Androgen Receptor-Low Triple-Negative Breast Cancer

Rida, P. C. G., Baker, S., Saidykhan, A., Bown, I., & Jinna, N. (2024) · Cancers · doi:10.3390/cancers16183191 · Cited by 6

Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors

Lingo, J. J., Voigt, E. M., & Quelle, D. E. (2024) · Oncotarget · doi:10.18632/oncotarget.28650 · Cited by 4

From Motor Proteins to Oncogenic Factors: The Evolving Role of Kinesin Superfamily Proteins in Breast Cancer Development

Saadh, M. J., Ahmed, H. H., Kareem, R. A., Chandra, M., Monsi, M., Walia, C., Prasad, G. V. S., Taher, W. M., Alwan, M., Jawad, M. J., et al. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01428-2 · Cited by 5

Identification of metabolic signatures related to metastasis and immunotherapy resistance in oral squamous cell carcinoma.

Chen, H., Liu, X., Yao, F., Yin, M., Cheng, B., & Yang, S. (2023) · PubMed Central · Cited by 5

The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells

Frezzetti, D., Caridi, V., Marra, L., Camerlingo, R., D’Alessio, A., Russo, F. P., Dotolo, S., Rachiglio, A. M., Abate, R. E., Gallo, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094844 · Cited by 5

Role and recent progress of P2Y12 receptor in cancer development

Xi, Y., Min, Z., Liu, M., Lin, X., & Yuan, Z.-H. (2024) · Purinergic Signalling · doi:10.1007/s11302-024-10027-w · Cited by 5

Modeling the effect of acquired resistance on cancer therapy outcomes

Masud, M. A., Kim, J., & Kim, E. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107035 · Cited by 5

Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies

Sanchez-Cespedes, M., Lockwood, W. W., Suda, K., Gardner, E. E., Mitsudomi, T., Politi, K., Rolfo, C., Sen, T., Sos, M. L., Tammela, T., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100944 · Cited by 5

Activation of Hippo/YAP signaling pathway exacerbates vascular remodeling and aggravates hypertension by upregulating Foxm1

Bai, J., & Yang, Y. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-025-10443-1 · Cited by 4

Kinesin superfamily proteins in ovarian cancer: from molecular mechanisms to clinical applications

Bishoyi, A. K., Al-Hasnaawei, S., Ganesan, S., Shankhyan, A., Nanda, A., Sinha, A., Ray, S., & Nathiya, D. (2025) · Medical Oncology · doi:10.1007/s12032-025-03044-1 · Cited by 4

Activating NEDD4L suppresses EGFR-driven lung adenocarcinoma growth via facilitating EGFR proteasomal degradation

Chen, M., Jiang, W., Zhan, J., Zhang, S., Zheng, J., Huang, Y., He, J., Yang, Y., Zhao, S. T., Zhang, Y., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03528-y · Cited by 4

Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway

Li, C., Shi, S., Li, L., Wang, Y., Yao, M., Yu, C., Yu, C., & Xie, C. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08220-9 · Cited by 4

Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model

Hagenbeek, T. J., Zbieg, J. R., Smith, R., Paul, S., Gerosa, L., Torrini, C., Guarnaccia, A. D., Ong, C. C., Lacap, J. A., Ning, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74722-5 · Cited by 4

High-risk histological subtype-related FAM83A hijacked FOXM1 transcriptional regulation to promote malignant progression in lung adenocarcinoma

Wei, F., Yan, Y., Liu, G., Peng, B., Liu, Y., & Chen, Q. (2023) · PeerJ · doi:10.7717/peerj.16306 · Cited by 4

ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC

Liu, Y., Yu, Y., Hu, C., Jiang, M., Zhao, C., Li, X., Cheng, L., & Zhou, C. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.206 · Cited by 4

Identification of Master Regulators Driving Disease Progression, Relapse, and Drug Resistance in Lung Adenocarcinoma

Xu, Q., Cha, Q., Qin, H., Liu, B., Wu, X., & Shi, J. (2022) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2022.813960 · Cited by 4

Construction and validation of risk model of EMT‐related prognostic genes for kidney renal clear cell carcinoma

Wu, L., Yuan, S., Lin, Q., Chen, G., Zhang, W., Zheng, W., & Lin, H. L. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3549 · Cited by 4

Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression

Ghosh, M., Wu, C., Kumar, A., Nilsson, M. B., Heymach, J. V., Zhao, W., Yu, J., Liu, X., Ding, N., Wang, S., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci198418 · Cited by 3

Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors

Cuellar-Vite, L., Donaubauer, E. M., Weber-Bonk, K. L., Bobbitt, J. R., Ingles, N. N., Brzozowski, T. L., Abdul‐Karim, F. W., Booth, C. N., & Keri, R. A. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0309 · Cited by 3

Molecular Mechanisms of Acquired Therapeutic Resistance to Tyrosine Kinase Targeted Therapy

Fu, L., & Luo, M. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_8 · Cited by 2

MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing

To, K. K. W., Leung, K., & Cho, W. C. S. (2023) · Drugs and Drug Candidates · doi:10.3390/ddc2030031 · Cited by 2

Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions

Rosell, R., Pedraz‐Valdunciel, C., Jain, A. S., Shivamallu, C., & Aguilar, A. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2320710 · Cited by 2

Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study

Jiang, K., Wu, L., Zheng, X., Xu, Y., Miao, Q., Zheng, X., Zhang, L., Huang, C., & Lin, G. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02905-1 · Cited by 2

Knockdown of Inhibin Beta A Reversed the Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Enhanced the Therapeutic Effect of Radiotherapy in Non-Small Cell Lung Cancer

Liu, H., Zhang, H., Yin, H., Wufuer, G., Wang, L., Abuduaini, S., & Chang, X. (2024) · Biochemical Genetics · doi:10.1007/s10528-024-10961-9 · Cited by 2

The abnormal expression of circ-ARAP2 promotes ESCC progression through regulating miR-761/FOXM1 axis-mediated stemness and the endothelial-mesenchymal transitionPreprint

Xu, P., Wang, L., Liu, Q., Gao, P., Hu, F., Xiao, X., Lianyong, J., Bi, R., Ding, F., Yang, Q., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1654959/v1 · Cited by 2

Radiomics and Radiogenomics Toward Personalized Management of Clear Cell Renal Cell Carcinoma: The Importance of FOXM1

Greco, F., & Mallio, C. A. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.07.044 · Cited by 1

Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation

Hosoya, K., Ozasa, H., Yoshida, H., Ajimizu, H., Tsuji, T., Yamazoe, M., Ogimoto, T., Hashimoto, K., Funazo, T. Y., Suminaga, K., et al. (2025) · Cancer Science · doi:10.1111/cas.70075 · Cited by 1

Baicalin inhibits A549 cells proliferation and EMT through targeting the EGFR pathway

Wang, Z., Lian, S., Liu, Z., & Zhou, W. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116011 · Cited by 1

Targeting the FOXM1/BUB1B signaling network in multiple myeloma: mechanistic insights and therapeutic potential

Yasin, D., Sami, N., Khalid, S., Zaheer, U., Rasool, Z., Faridi, F., Asmar, M., & Uddin, S. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2612628 · Cited by 1

GPNMB-ECD drives acquired resistance to osimertinib in NSCLC via inducing tumor cell cytoskeletal reorganization

Zhang, M., Wang, J.-Q., Yang, X. L., Liu, W. T., Huang, Y., Wen, C., Chen, D., & Wu, L. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00965-1 · Cited by 1

Development of gemcitabine-modified multimodal miR-129 mimic as a novel therapeutic in non-small cell lung cancer

Intriago, E., Pal, A. S., Ojha, A., Cui, M., Pesselev, I. Y., Coant, N., Guo, I., Haley, J., & Ju, J. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102997 · Cited by 1

Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance

Chen, Y., Liu, Q.-P., Yang, S.-J., Ding, J., Lu, X.-Y., & Xie, H. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01855-0 · Cited by 1

Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer

Tanabe, S., Boonstra, E., Hong, T., Quader, S., Ono, R., Cabral, H., Aoyagi, K., Yokozaki, H., Perkins, E. J., & Sasaki, H. (2023) · Genes · doi:10.3390/genes14112073 · Cited by 1

Induction of Multiple Alternative Mitogenic Signaling Pathways Accompanies Emergence of Slowly Growing Drug-Tolerant Cancer CellsPreprint

Celeste, F., & Powers, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1598602/v1 · Cited by 1

Targeting CDA-Directed Metabolism With 5-Formyl-2'-Deoxycytidine For ALK Inhibitor–Resistant Lung Cancer TherapyPreprint

Heo, H., Kim, J.-H., Lim, H. J., Kim, J., Kim, M., Koh, J., Im, J., Kim, B., Won, M., Park, J.-H., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1110449/v1

FoxM1 contributes to progestin resistance and epithelial-to-mesenchymal transition in endometrial carcinoma

Wang, L., Shi, Q., & Chen, S. (2022) · Molecular & Cellular Toxicology · doi:10.1007/s13273-022-00251-z

Location of EGFR exon 20 insertions matters

Cardona, A. F., González‐Cao, M., Arrieta, O. G., & Rosell, R. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.002

Epithelial-mesenchymal transition and resistance to EGFR inhibitors

Jacob, S., Kurupi, R., & Faber, A. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00009-7

Role of epithelial to mesenchymal transition in the resistant mechanism of EGFR-TKIs

Adachi, Y., & Ebi, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00005-x

YY2/BUB3 axis-mediated SAC hyperactivity determines tumor cell fate through chromosomal instabilityPreprint

Hosea, R., Duan, W., Meliala, I. T. S., Li, W., Wei, M., Hillary, S., Zhao, H., Miyagishi, M., Wu, S., & Kasim, V. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.07.561167

The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells

Xiaoyang, D. A. I., Liu, X., Ge, F., Hongdao, Z. H. U., Zheng, C., Yan, F., & Yang, B. (2023) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2023-0305

Pan-Cancer transcriptomics reveals diverse R-loop events based on multiple machine learning algorithmsPreprint

Jiang, B., Zhang, Y., & Chen, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-3785133/v1

The prognostic significance of FoxM1 and its immune regulatory function in Liver Hepatocellular CarcinomaPreprint

Li, C., Yao, Q., Chen, C., Bu, X., Ma, X., & Zhao, P. (2024) · Research Square · doi:10.21203/rs.3.rs-3955595/v1

Additional file 1 of The abnormal expression of circ-ARAP2 promotes ESCC progression through regulating miR-761/FOXM1 axis-mediated stemness and the endothelial–mesenchymal transition

Xu, P., Wang, L., Liu, Q., Gao, P., Hu, F., Xie, X., Lianyong, J., Bi, R., Ding, F., Yang, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20329809

Additional file 2 of The abnormal expression of circ-ARAP2 promotes ESCC progression through regulating miR-761/FOXM1 axis-mediated stemness and the endothelial–mesenchymal transition

Xu, P., Wang, L., Liu, Q., Gao, P., Hu, F., Xie, X., Lianyong, J., Bi, R., Ding, F., Yang, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20329815

Inflammatory damage caused by Echovirus 30 in the suckling mouse brain and HMC3 cells

Li, J., Zong, Y., Sun, T., Liu, Y., Wang, R., Zhou, J., Sun, Q., & Zhang, Y. (2024) · Virology Journal · doi:10.1186/s12985-024-02437-4

Osimertinib resistance-based immune prognostic related gene signature in EGFR mutant lung adenocarcinoma, in which PSMD11 promotes tumor progression

Bai, Y., He, X., Bao, P., Gao, Y., Sun, J., Shen, Y., Zhao, J., & Jiang, T. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-355

Additional file 3 of The abnormal expression of circ-ARAP2 promotes ESCC progression through regulating miR-761/FOXM1 axis-mediated stemness and the endothelial–mesenchymal transition

Xu, P., Wang, L., Liu, Q., Gao, P., Hu, F., Xie, X., Jiang, L., Bi, R., Ding, F., Yang, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20329818

Cellular Prion Protein (PrPC) Drives Epithelial–Mesenchymal Transition and EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer

Pereira, K., Bianchi, W. P., Garcia, D., Martinez, C. H., Lucia, L. I., & Nakamura, S. X. (2023) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/27lsdbu1hx

ELMO2 is a therapeutic vulnerability in mesenchymal-like and drug-resistant non-small cell lung cancer

Li, M., Xue, Y.-X., Chang, Y.-I., Xu, F., Wu, F., Tian, X.-J., Hu, J., Song, Y.-J., Yu, X.-F., Zhou, F., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72062-y

Pleomorphic Carcinoma With EGFR and Concomitant Mutations Transformed From Lung Adenocarcinoma: A Case Report

Akazawa, Y., Sato, T., Yagami, Y., Kesen, Y., Furo, T., WATANABE, A., Jumpei, E. N. D. O., Nakano, M., Kurata, H., Matsuo, H., et al. (2026) · Cancer Reports · doi:10.1002/cnr2.70546

STRIP2 confers acquired resistance to EGFR-TKIs in lung adenocarcinoma by modulating IGF2BP3-dependent Twist1 stability

Zhang, X., Gu, J., Lei, Z., Zhang, R., Ling, Y., Xie, Y., Tang, C., He, Y., & Wang, W. (2026) · Genomics · doi:10.1016/j.ygeno.2026.111262

Multidimensional regulatory networks of drug resistance in colorectal cancer: from molecular mechanisms to novel therapeutic counterstrategies

Shen, J., Ma, Y., Wang, Y., Yang, M., Liang, T., & Guo, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118184

Epidermal growth factor receptor activation is associated with NSCLC cells resistance to ferroptosis and correlates with ROS-NRF2-GCLC/GCLM pathway activation

Wang, L., Wang, Y., Li, Y., Wu, S., Zhou, C., Gao, Y., Ren, M., Na, R., Wang, Y., 张得时, et al. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112912

DYT8 drives lung adenocarcinoma through EGFR-mediated PSMC6 recruitment and uncharacterized phosphorylation at Ser 306 and 525 of c-Src.

Cai, M.-L., Wang, M.-Y., Zhao, X.-J., Xing, Y., Liu, H.-Z., Shao, R.-G., Chen, M.-H., & Zhao, W.-L. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01948-w

IA34 The YAP/FOXM1 Axis Regulates EMT-Associated EGFR Tyrosine Kinase Inhibitor Resistance and Increased Expression of Spindle Assembly Checkpoint Components

Nilsson, M. B., Sun, H., Robichaux, J. P., Diao, L., Xi, Y., Tong, P., Sheng, L., Hofstad, M. E., Kawakami, M., Le, X., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.123 · Cited by 1

Abstract 1960: T790M-independent EGFR TKI resistance is associated with a broad multi-drug resistant phenotype but selective vulnerabilities to spindle assembly complex (SAC) and CDK inhibitors

Nilsson, M. B., Robichaux, J., Sun, H., Tong, P., Diao, L., Hofstad, M. E., Fan, Y.-H., Wang, J., & Heymach, J. V. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-1960

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors

McGowan, M., Kleinberg, L., Halvorsen, A. R., Helland, Å., & Brustugun, O. T. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.136 · Cited by 65

Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma

Shi, R., Farnsworth, D., Febres‐Aldana, C. A., Chow, J. L. M., Sheena, R., Atwal, T., Marti, J. L. G., Li, S., Thomas, K. N., Lee, C.-M., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03461-6 · Cited by 13

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC

Ghiso, E., Migliore, C., Ciciriello, V., Morando, E., Petrelli, A., Corso, S., Luca, E. D., Gatti, G., Volante, M., & Giordano, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.10.003 · Cited by 101